Study S001397

Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT01562678
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: TRIPLE
Status: COMPLETED
Enrollment: 28
Start: 2012-03
Primary completion: 2014-05
Lead sponsor: Beth Israel Deaconess Medical Center
Conditions: Diabetes; Effects of Liraglutide Administration on Brain Activity; Weight Loss; Hunger
Interventions: DRUG:Liraglutide; DRUG:Placebo
Results posted: TRUE

Registered primary outcomes

Change Between Highly Desirable vs. Less Desirable Food Cues in the Effect Size of Cortical Activation During Food Visualization [18 days of Liraglutide or placebo treatment]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0009442	Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity. Angelidi AM, Metabolism: clinical and experimental	2023	Randomized trial	PMID 36375643 DOI	cites ClinicalTrials.gov:NCT01562678; registry reference DERIVED:36375643
R0022856	GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Farr OM, Diabetologia	2016	Randomized trial	PMID 26831302 DOI	cites ClinicalTrials.gov:NCT01562678; registry reference DERIVED:26831302